DrugPatentWatch Database Preview
Triamcinolone acetonide - Generic Drug Details
What are the generic drug sources for triamcinolone acetonide and what is the scope of patent protection?
Triamcinolone acetonide
is the generic ingredient in twenty-seven branded drugs marketed by Abbvie, Sanofi Aventis Us, Astellas, Ivax Pharms, Delcor Asset Corp, Teva, Solvay, Acp Nimble, Actavis Mid Atlantic, Alkem Labs Ltd, Alpharma Us Pharms, Ambix, Fougera Pharms, Glenmark Pharms Ltd, Lupin Atlantis, Macleods Pharms Ltd, Morton Grove, Mylan, Perrigo New York, Pharmaderm, Pharmafair, Saptalis Pharms, Strides Pharma, Taro, Taro Pharm Inds Ltd, Teligent Pharma Inc, Topiderm, Crown Labs, Savage Labs, Flexion Theraps Inc, Apothecon, Amneal Pharms Co, Parnell, Sandoz Inc, Teva Pharms Usa, Watson Labs, Allergan, Novartis Pharms Corp, Akorn, Wockhardt Bio Ag, Glenmark Pharms, Novel Labs Inc, Cmp Pharma Inc, Lyne, Perrigo Israel, Sun Pharm Inds Inc, Perrigo Uk Finco, and Rising, and is included in one hundred and twenty-five NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Triamcinolone acetonide has seventy patent family members in twenty-four countries.
There are fifty-one drug master file entries for triamcinolone acetonide. Seventy suppliers are listed for this compound.
Summary for triamcinolone acetonide
| International Patents: | 70 |
| US Patents: | 5 |
| Tradenames: | 27 |
| Applicants: | 48 |
| NDAs: | 125 |
| Drug Master File Entries: | 51 |
| Suppliers / Packagers: | 70 |
| Bulk Api Vendors: | 64 |
| Clinical Trials: | 156 |
| Patent Applications: | 6,662 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for triamcinolone acetonide |
| Drug Sales Revenues: | Drug sales revenues for triamcinolone acetonide |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for triamcinolone acetonide |
| DailyMed Link: | triamcinolone acetonide at DailyMed |
Recent Clinical Trials for triamcinolone acetonide
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institute of Nursing Research (NINR) | Phase 2 |
| Wake Forest University Health Sciences | Phase 4 |
| Emory University | Phase 2 |
Recent Litigation for triamcinolone acetonide
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Aventis Pharmaceuticals Inc. v. Barr Laboratories Inc. | 2006-05-02 |
Pharmacology for triamcinolone acetonide
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for triamcinolone acetonide
Synonyms for triamcinolone acetonide
| (11beta,16alpha)-9-Fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione |
| (4aS,4bR,5S,6aS,6bR,9aR)-4b-fluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one |
| (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS)-4b-fluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one |
| (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS)-4b-fluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one |
| (6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-6b-fluoro-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[ |
| 056T834 |
| 1,2-d][1,3]dioxol-4-one |
| 13586-95-3 |
| 138265-06-2 |
| 1TA |
| 5-19-06-00568 (Beilstein Handbook Reference) |
| 76-25-5 |
| 8054-16-8 |
| 9-alpha-Fluoro-11-beta,21-dihydroxy-16-alpha-isopropylidenedioxy-1,4-pregnadiene,3,20-dione |
| 9-alpha-Fluoro-11-beta,21-dihydroxy-16-alpha,17-alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione |
| 9-alpha-Fluoro-16-alpha-17-alpha-isopropyledenedioxyprednisolone |
| 9-alpha-Fluoro-16-alpha-17-alpha-isopropylidenedioxy-delta-1-hydrocortisone |
| 9-alpha-Fluoro-16-alpha-hydroxyprednisolone 16-alpha,17-alpha-acetonide |
| 9-alpha-Fluoro-16-hydroxyprednisolone acetonide |
| 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone |
| 9-fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione-16,17-acetonide |
| 9?-Fluoro-11?,21-dihydroxy-16?,17?-isopropylidenedioxypregna-1,4-diene-3,20-dione |
| 9.alpha.-Fluoro-11.beta.,4-pregnadiene,3,20-dione |
| 9.alpha.-Fluoro-16-hydroxyprednisolone acetonide |
| 9.alpha.-Fluoro-16.alpha.-17.alpha.-isopropyledenedioxyprednisolone |
| 9.alpha.-Fluoro-16.alpha.-17.alpha.-isopropylidenedioxy-.delta.-1-hydrocortisone |
| 9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone 16.alpha.,17.alpha.-acetonide |
| 9|A-Fluoro-11|A,21-dihydroxy-16|A,17-isopropylidenedioxy-1,4-pregnadiene-3,20-dione |
| 911437-91-7 |
| 9A-FLUORO-11B,16A,17A,21-TETRAHYDROXY-1,4-PREGNADIENE-3,20-DIONE 16,17-ACETONIDE |
| 9alpha-Fluoro-11beta,21-dihydroxy-16alpha,17-isopropylidenedioxy-1,4-pregnadiene,3,20-dione |
| 9alpha-fluoro-11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione |
| 9alpha-Fluoro-16-hydroxyprednisolone acetonide |
| 9alpha-Fluoro-16alpha-17alpha-isopropyledenedioxyprednisolone |
| 9alpha-fluoro-16alpha-17alpha-isopropylidenedioxy-Delta-1-hydrocortisone |
| 9alpha-Fluoro-16alpha-hydroxyprednisolone 16alpha,17alpha-acetonide |
| AB00383012_12 |
| AB00383012-11 |
| AB1010917 |
| AC-1239 |
| AC1L1MJ3 |
| AC1Q2CRE |
| Acetospan |
| ACN-043361 |
| Adcortyl A |
| AKOS015894871 |
| AllerNaze |
| alpha-Fluoro-11beta,16alpha,17,21-tetra-hydroxypregna-1,4-diene-3,20-dione |
| AN-15131 |
| Aristocort A |
| Aristocort acetonide |
| Aristoderm |
| Aristogel |
| Asmacort [Common Misspelling of Azmacort] |
| Azmacort |
| BRD-K53790871-001-08-6 |
| BRN 0060069 |
| C-22292 |
| C08183 |
| CAS-76-25-5 |
| CCRIS 5231 |
| CHEBI:71418 |
| CHEMBL1504 |
| Cinonide |
| Coupe-A |
| CS-2871 |
| D00983 |
| DSSTox_CID_1371 |
| DSSTox_GSID_21371 |
| DSSTox_RID_76115 |
| DTXSID6021371 |
| EINECS 200-948-7 |
| F446C597KA |
| Flutex |
| Flutone |
| fx-006 |
| FX006 |
| GTPL2867 |
| HMS2232F22 |
| HMS3259A20 |
| HY-B0636 |
| J10453 |
| Kenacort A |
| Kenacort-A |
| Kenalog |
| Kenalog 40 |
| Kenalog in Orabase |
| Kenalog-10 |
| Kenalog-40 |
| Kenalog-H |
| Kenalone |
| KS-5330 |
| LS-1692 |
| MFCD00056834 |
| MLS000028538 |
| MLS001148264 |
| MLS002207192 |
| MLS002638825 |
| MolPort-002-529-154 |
| Nasacort |
| Nasacort Allergy 24 Hour |
| Nasacort AQ |
| Nasacort HFA |
| NC00591 |
| NCGC00023193-04 |
| NCGC00023193-05 |
| NCGC00023193-06 |
| NCGC00256560-01 |
| NCGC00259344-01 |
| NSC 21916 |
| NSC-21916 |
| NSC21916 |
| Omcilon A |
| Opera_ID_232 |
| Oracort |
| Oralone |
| Panolog Ointment (Veterinary) |
| Pregna-1,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11.beta.,16.alpha.)- |
| Pregna-1,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone |
| Pregna-1,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-,cyclic 16,17-acetal with acetone |
| Pregna-1,20-dione, 9-fluoro-11.beta.,21-dihydroxy-16.alpha.,17-(isopropylidenedioxy)- |
| Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone |
| Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11beta,16alpha)- |
| Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone |
| Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (8CI) |
| Q-201855 |
| Rineton |
| S1628 |
| SCHEMBL4689 |
| SMR000058335 |
| Solodelf |
| ST24050240 |
| TAC-3 |
| Tox21_110885 |
| Tox21_110885_1 |
| Tox21_201795 |
| Tox21_303014 |
| Tramacin |
| Tri-Nasal |
| Triacet |
| Triaceton |
| Triacort |
| Triam-Injekt |
| Triamcincolone acetonide |
| Triamcinolone (acetonide) |
| Triamcinolone 16,17-acetonide |
| Triamcinolone acetonide (JP17/USP) |
| TRIAMCINOLONE ACETONIDE (SEE ALSO TRIAMCINOLONE (124-94-7)) |
| Triamcinolone acetonide [JAN] |
| Triamcinolone acetonide [USP:INN:BAN:JAN] |
| Triamcinolone acetonide for system suitability, European Pharmacopoeia (EP) Reference Standard |
| Triamcinolone Acetonide in Absorbase |
| Triamcinolone acetonide, analytical standard |
| Triamcinolone acetonide, European Pharmacopoeia (EP) Reference Standard |
| Triamcinolone Acetonide, Pharmaceutical Secondary Standard; Certified Reference Material |
| Triamcinolone acetonide, United States Pharmacopeia (USP) Reference Standard |
| Triamonide 40 |
| Triamsinolone acetonide |
| Trianex |
| Triatex |
| Tricinolon |
| Tricort-40 |
| Triderm |
| Triesence |
| Trivaris |
| Trymex |
| UNII-F446C597KA |
| Vetalog |
| Vetalog (Veterinary) |
| Volon A |
| Volon A 40 |
| VZ33964 |
| WLN: T F5 E5 B666 GO IO RV AHTTTT&J A1 BF CQ E1 FV1Q H1 H1 |
| YNDXUCZADRHECN-JNQJZLCISA-N |
| Zilretta |
| ZINC3875481 |
US Patents and Regulatory Information for triamcinolone acetonide
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Perrigo Israel | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | SPRAY, METERED;NASAL | 078104-002 | Nov 14, 2014 | OTC | No | No | Start Trial | Start Trial | Start Trial | ||||
| Solvay | TRIACORT | triamcinolone acetonide | CREAM;TOPICAL | 087113-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Fougera Pharms | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | CREAM;TOPICAL | 085692-002 | Approved Prior to Jan 1, 1982 | AT | RX | No | Yes | Start Trial | Start Trial | Start Trial | |||
| Teva | TRIACET | triamcinolone acetonide | CREAM;TOPICAL | 084908-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Alkem Labs Ltd | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | CREAM;TOPICAL | 207651-003 | Dec 26, 2017 | AT | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for triamcinolone acetonide
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | NASACORT ALLERGY 24 HOUR | triamcinolone acetonide | SPRAY, METERED;NASAL | 020468-002 | Oct 11, 2013 | Start Trial | Start Trial |
| Abbvie | AZMACORT | triamcinolone acetonide | AEROSOL, METERED;INHALATION | 018117-001 | Apr 23, 1982 | Start Trial | Start Trial |
| Sanofi Aventis Us | NASACORT | triamcinolone acetonide | AEROSOL, METERED;NASAL | 019798-001 | Jul 11, 1991 | Start Trial | Start Trial |
| Delcor Asset Corp | KENALOG-H | triamcinolone acetonide | CREAM;TOPICAL | 086240-001 | Approved Prior to Jan 1, 1982 | Start Trial | Start Trial |
| Sanofi Aventis Us | NASACORT ALLERGY 24 HOUR | triamcinolone acetonide | SPRAY, METERED;NASAL | 020468-002 | Oct 11, 2013 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for triamcinolone acetonide
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 2262506 | Start Trial |
| South Korea | 20100127267 | Start Trial |
| Uruguay | 31699 | Start Trial |
| Mexico | 2013001433 | Start Trial |
| Japan | 5873492 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
Major Patent Expirations 2019 - 2020
NCE-1 Generic Application Dates 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
Major Patent Expirations 2019 - 2020
NCE-1 Generic Application Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.